For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Repligen Corp (NASDAQ: RGEN) closed at $166.52 up 0.91% from its previous closing price of $165.02. In other words, the price has increased by $0.91 from its previous closing price. On the day, 0.92 million shares were traded. RGEN stock price reached its highest trading level at $170.4 during the session, while it also had its lowest trading level at $165.04.
Ratios:
For a deeper understanding of Repligen Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 88.03. For the most recent quarter (mrq), Quick Ratio is recorded 7.14 and its Current Ratio is at 8.36. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.32.
Upgrades & Downgrades
In the most recent recommendation for this company, HSBC Securities on October 01, 2025, initiated with a Buy rating and assigned the stock a target price of $150.
On September 22, 2025, Evercore ISI Upgraded its rating to Outperform which previously was In-line but kept the price unchanged to $155.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 25 ’25 when Loeillot Olivier sold 7,041 shares for $170.00 per share. The transaction valued at 1,196,970 led to the insider holds 35,898 shares of the business.
Loeillot Olivier bought 7,041 shares of RGEN for $1,196,970 on Nov 25 ’25. On Nov 18 ’25, another insider, Bylund James, who serves as the Chief Operating Officer of the company, sold 2,191 shares for $151.21 each. As a result, the insider received 331,301 and left with 21,520 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 9373535232 and an Enterprise Value of 9313655808. As of this moment, Repligen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6479.38, and their Forward P/E ratio for the next fiscal year is 79.58. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 325.27. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.24 while its Price-to-Book (P/B) ratio in mrq is 4.50. Its current Enterprise Value per Revenue stands at 13.157 whereas that against EBITDA is 67.873.
Stock Price History:
The Beta on a monthly basis for RGEN is 1.12, which has changed by 0.15998876 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $182.52, while it has fallen to a 52-week low of $102.96. The 50-Day Moving Average of the stock is 10.09%, while the 200-Day Moving Average is calculated to be 23.69%.
Shares Statistics:
For the past three months, RGEN has traded an average of 945.56K shares per day and 727680 over the past ten days. A total of 56.28M shares are outstanding, with a floating share count of 53.21M. Insiders hold about 5.47% of the company’s shares, while institutions hold 107.06% stake in the company. Shares short for RGEN as of 1763078400 were 4085106 with a Short Ratio of 4.32, compared to 1760486400 on 3382265. Therefore, it implies a Short% of Shares Outstanding of 4085106 and a Short% of Float of 9.7799994.
Earnings Estimates
. The current rating of Repligen Corp (RGEN) is the result of assessments by 18.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.45, with high estimates of $0.51 and low estimates of $0.31.
Analysts are recommending an EPS of between $1.7 and $1.65 for the fiscal current year, implying an average EPS of $1.67. EPS for the following year is $2.09, with 19.0 analysts recommending between $2.47 and $1.76.
Revenue Estimates
A total of 18 analysts believe the company’s revenue will be $192.78M this quarter.It ranges from a high estimate of $194.25M to a low estimate of $189M. As of. The current estimate, Repligen Corp’s year-ago sales were $167.55MFor the next quarter, 18 analysts are estimating revenue of $191.51M. There is a high estimate of $195.82M for the next quarter, whereas the lowest estimate is $186.8M.
A total of 20 analysts have provided revenue estimates for RGEN’s current fiscal year. The highest revenue estimate was $734.6M, while the lowest revenue estimate was $729.3M, resulting in an average revenue estimate of $732.98M. In the same quarter a year ago, actual revenue was $634.44MBased on 19 analysts’ estimates, the company’s revenue will be $825.24M in the next fiscal year. The high estimate is $847.15M and the low estimate is $794.14M.
